All In Biotech

Drug Trial Radar · NCT07076199

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 877 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

877

Planned (sponsor's estimate)

Start

Aug 11, 2025

Primary completion

Jan 25, 2027

Study completion Mar 1, 2027

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jul 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • Insulin icodecDrug

    Insulin icodec will be administered as subcutaneous injection

  • Insulin glargineDrug

    Insulin glargine will be administered as subcutaneous injection.

  • Insulin aspartDrug

    Insulin aspart will be administered as a subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in glycosylated haemoglobin (HbA1c)Time frame: From baseline (week 0) to week 26

Locations

182 sites in 8 countries. Site status is shown where the registry gives one.

  • Cullman Clinical Trials

    Cullman, Alabama

  • John Muir Health

    Concord, California

  • Headlands Research California, LLC

    Escondido, California

  • Clinical Res of Central Ca

    Fresno, California

  • Providence Medical Foundation

    Fullerton, California

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • Loma Linda University Faculty Medical Clinics

    Loma Linda, California

  • Pacific Clinical Studies

    Los Alamitos, California

  • Los Angeles Institute for Metabolic Research

    Los Angeles, California

  • Pasadena Clinical Trials

    Pasadena, California

  • WestenU Health

    Pomona, California

  • Alliance Clinical Network

    San Diego, California

  • Mills Health Center

    San Mateo, California

  • Center for Endocrine DM and Metabolic Disorders

    Santa Clarita, California

  • University Clin Investigators

    Tustin, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Denver Endocrinology Diabetes and Thyroid Center

    Englewood, Colorado

  • Optumcare Clinical Trials,LLC-Golden

    Golden, Colorado

  • Northeast Research Institute

    Fleming Island, Florida

  • Encore Medical Research LLC

    Hollywood, Florida

  • Northeast Research Institute

    Jacksonville, Florida

  • Life Spring Research Foundation LLC

    Miami, Florida

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida

  • West Orange Endocrinology

    Ocoee, Florida

  • Suncoast Clinical Research, Inc.

    Palm Harbor, Florida

  • Center for Diab,Obes & Metab

    Pembroke Pines, Florida

  • SRA Trials-Broward

    Pembroke Pines, Florida

  • Hanson Clinical Research Center

    Port Charlotte, Florida

  • Latin Clinical Trial Ctr

    Tamarac, Florida

  • Bayside Clinical Research

    Tampa, Florida

  • Metabolic Research Institute Inc

    West Palm Beach, Florida

  • Atlanta Diabetes Associates

    Atlanta, Georgia

  • Centricity Research Columbus

    Columbus, Georgia

  • Physicians Research Assoc. LLC

    Lawrenceville, Georgia

  • Endocrine Research Solutions, Inc

    Roswell, Georgia

  • Rocky Mt Clin Res, LLC

    Idaho Falls, Idaho

  • Northwestern University

    Chicago, Illinois

  • University Of Chicago

    Chicago, Illinois

  • Endeavor Health

    Skokie, Illinois

  • Indiana Uni School of Med-Ped

    Indianapolis, Indiana

Showing 40 of 182 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.